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Abstract
SALL4 is a zinc finger DNA-binding protein that has been well characterized in devel-
opment and in embryonic stem cell (ESC) maintenance. Notably, SALL4 may be one of 
the few genes that are also involved in tissue stem cells in adults, and SALL4 protein 
expression has been correlated with the presence of stem and progenitor cell popula-
tions in various organ systems and also in human cancers. In normal hematopoiesis, 
SALL4 expression is restricted to the rare hematopoietic stem/progenitor cell (HSC/
HPC) fractions but is rapidly silenced following lineage differentiation. In hematopoi-
etic malignancies, however, SALL4 is persistently expressed and its expression levels are 
linked with deteriorated disease status. Furthermore, SALL4 activation participates in 
the pathogenesis of tumor initiation and disease progression. This chapter summarizes 
recent advances in our knowledge of SALL4 biology with a focus on its regulatory func-
tions in normal and leukemic hematopoiesis. A better understanding of SALL4’s biologic 
functions and mechanisms is needed to facilitate the development of advanced therapies 
in future.
Keywords: pluripotency, leukemogenesis, hematopoietic stem/progenitor cell,  
MLL-rearrangement, epigenetic, histone methylation, DNA methylation, differentiation, 
zinc finger domain
1. Introduction
SALL4 is one of four human homologs (SALL-1, -2, -3, -4) of the Drosophila region-specific 
gene Spalt (sal). In Drosophila, sal is a homeotic gene essential for development of posterior 
head and anterior tail segments. As a DNA-binding transcription factor, the SALL4 protein is 
characterized by multiple Cys2His2 zinc finger (C2H2-ZF) domain distributed over the entire 
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protein [1–3]. In mammals, the expression of SALL4 has been primarily detected in ESCs and 
in adult tissue “stem-like” cells, where it mainly activates pluripotency and/or multipotency 
genes and suppresses differentiation-related genes, thereby modulating the cell “stemness” 
in development and in tissue generation [4–8]. In humans, heterozygous SALL4 mutation has 
been linked to Okihiro syndrome, Holt-Oram syndrome, acro-renal-ocular syndrome, and 
IVIC syndrome, all characterized by multiple organ malformations [9–11]. While normally 
downregulated or no longer expressed in fully differentiated somatic cells, abnormal reacti-
vation of SALL4 in adult cells may lead to malignancy. To date, aberrant SALL4 expression 
has been detected in over 10 types of human solid tumors and in several common types of 
leukemias, and SALL4 has been considered a useful biomarker for these diseases [7, 8, 12, 
13]. In addition, studies suggest that SALL4 may be a therapeutic target in treating human 
leukemias [12, 13]. For these reasons, it will be important to understand how SALL4, a criti-
cal pluripotency factor, exerts its effects in different cell contexts, and how we can effectively 
translate our knowledge gains into treatment breakthroughs in future.
2. SALL4 roles in stem cells and development
2.1. The roles of SALL4 in ESC property maintenance and embryonic development
SALL4 has been one of the most studied transcriptional regulators in ESC self-renewal and 
pluripotency maintenance. It has been reported that in human ESCs, a well-controlled SALL4/
OCT4 transcription regulatory loop balances proper expression dosage of SALL4 and OCT4; 
and reduction of SALL4, like OCT4, results in re-specification of ESCs to the trophoblast lineage 
[14–17]. In mouse ESC studies, chromatin immunoprecipitation coupled to microarray hybrid-
ization (ChIP-on-chip) revealed that SALL4 binds to about twice as many gene promoters as 
NANOG and binds about four times more genes than OCT4; and the three factors were found 
to form heteromeric protein complex in regulating stem cell pluripotency. Further, SALL4 
binds many genes that are regulated by chromatin-based epigenetic events mediated by cohe-
sin complex, polycomb-repressive complexes 1 and 2 (PRC1 and PRC2), and bivalent domains 
[18, 19]. Thus, SALL4 plays a diverse role in regulating stem cell pluripotency (see Figure 1).
In early embryonic development, SALL4 expression in mouse is detected at as early as the 
two cell stage. At the blastocyst stage, SALL4 expression becomes enriched in the inner cell 
mass (ICM) and the trophectoderm [17, 20–22]. Reduction of SALL4 in oocytes and ESCs 
results in early embryo defects, and disruption of both Sall4 alleles causes embryonic lethal-
ity during peri-implantation [23–25]. SALL4 is also expressed in extraembryonic endoderm 
(XEN) cells, where it participates in cell fate decision by simultaneously activating pluripo-
tency-maintaining factors and silencing endoderm lineage-associated factors such as GATA6, 
GATA4, and SOX17 [26, 27]. During subsequent stages, heterozygous disruption of Sall4 allele 
leads to multi-organ malformations including limb and heart defects, which model human 
disease [25]. It has been reported that TBX5, a gene encoding a T-box transcription factor, 
regulates SALL4 expression in the developing forelimb and heart, and interacts with SALL4 
to synergistically regulate downstream gene expression [24, 25, 28].
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2.2. SALL4 is a potent regulator in reprogramming somatic cells to pluripotency
Decreased SALL4 expression in ESCs has been shown to downregulate the expression levels 
of Oct4, Sox2, Klf4, and c-Myc (OSKM), the four proteins capable of reprogramming murine 
somatic cells to an induced pluripotent state [18, 29]. Consistently, knockdown of SALL4 in 
fibroblasts decreased the efficiency of induced pluripotent stem cell (iPSC) generation, while 
overexpression of SALL4 significantly increased iPSC generation [30, 31]. In a recent study 
by Shu et al., the GATA family members GATA4 and GATA6 have been found to substi-
tute for OCT4 in mouse somatic reprogramming, and SALL4 is identified as a major target 
gene of the GATA members [32]. In another study by Buganim et al., ectopic expression of 
SALL4, NANOG, ESRRB, and LIN28 in mouse fibroblasts generated high-quality iPSCs more 
Figure 1. SALL4 plays a variety of regulatory functions in maintaining and/or reprogramming cells to pluripotency. 
PRC: polycomb-repressive complexes.
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efficiently than the combination of OSKM [33]. Similarly, Mansour et al., showed that the 
combined overexpression of SALL4 with stem cell factors SALL1, UTF1, NANOG and MYC 
also replaced exogenous OSK expression and generated chimaera formation- competent iPSC 
clones [34]. Together, these studies suggest that SALL4 not only plays a role in ESC property 
maintenance, but its overexpression also drives reprogramming of somatic cells toward a 
stem cell-like fate (see Figure 1).
2.3. SALL4 regulates distinct transcriptional networks in ESCs and XEN cells
SALL4 appears to be unique among the core ESC pluripotency regulators because it is also 
expressed in non-ESC stem cell fractions where Oct4 and/or Nanog are silenced. These include 
XEN cells, mesodermal progenitor cells [35], embryonic cardiac progenitor cells [36], fetal 
liver stem/progenitor cells [27], and adult stem cells such as bone marrow HSCs/HPCs [37]. 
In these cells, SALL4 regulates downstream networks in a cell type-specific manner. Genome-
wide promoter binding assays in murine ESCs and XEN cells revealed that SALL4 regulates 
disparate gene sets in these cells, and down-regulation of SALL4 targets in the respective cell 
types induced differentiation [26]. Also consistent with the previous report [18], Sall4, Oct4, 
Sox2, and Nanog in murine ESCs formed a crucial interconnected autoregulatory network. 
In XEN cells however, SALL4 regulates the key XEN lineage-associated genes Gata4, Gata6, 
Sox7, and Sox17 (see Figure 2). Moreover, transcription assays revealed that SALL4 regulates 
Figure 2. SALL4 binds and regulates distinct target genes in ESCs and XEN cells. Shown are examples of such genes in 
each cell types. Figure modified from Ref. [26].
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the expression of more than half of its binding genes in ESCs, but downregulation of SALL4 
did not result in similar expression changes in the majority of these genes in XEN cells [26].
3. Functions of SALL4 and its regulated networks in normal 
hematopoiesis
3.1. The SALL4 isoforms are robust simulators for HSC/HPC ex vivo expansion
In humans and mice, the SALL4 proteins exist in at least three isoforms termed A, B and C, 
with SALL4A (full length) and SALL4B (lacks a portion of exon2 sequence) being the most 
studied [38–40]. To date, the function of SALL4C isoform (exon2 sequence spliced out) has 
not been well characterized. In the human blood system, the cellular expressions of SALL4 
isoforms have been originally investigated by immunofluorescence staining and qRT-PCR 
assays, which revealed that both A and B isoforms are highly expressed in bone marrow 
CD34+CD38− HSCs, downregulated in CD34+CD38+ HPCs, and absent in CD34− differenti-
ated lineage cells. Similarly, the SALL4 -A and -B isoforms in mouse bone marrows were 
found selectively expressed in the nuclei of Lin-Sca1+cKit+ (LSK) HSCs. The functions of 
SALL4 in the self-renewal of HSCs/HPCs have been explored. We and others reported that 
the SALL4 isoforms are robust stimulators for CD34+ (or CD133+) HSCs/HPCs ex vivo expan-
sion, and the SALL4-mediated cell expansion was associated with enhanced cell engraftment 
and long-term repopulation capacity in transplanted mice [40–44]. In mouse model studies, 
forced overexpression of the SALL4 isoforms in bone marrow LSK cells likewise leads to 
sustained cell proliferation, as well as enhanced marrow-repopulating potential in vivo [39]. 
By transcripts assays, the increased HSC/HPC growth was found associated with upregula-
tion of important HSC regulatory genes including HOXB4, NOTCH1, BMI1, RUNX1, CMYC, 
MEIS1 and NF-YA [39]. Further, in a myeloid progenitor cell line (32D cell) study, overexpres-
sion of the SALL4 isoforms blocked granulocyte-colony stimulating factor (G-CSF)-induced 
granulocytic differentiation, and permitted expansion of undifferentiated cells in the presence 
of defined cytokines [39, 40]. Thus, the SALL4 isoforms stimulate HSC/HPC proliferation 
by activating important self-renewal regulators and simultaneously inhibiting cellular dif-
ferentiation. These studies provide a new avenue for investigating mechanisms of SALL4-
regulated HSC/HPC self-renewal and potentially achieving clinically significant expansion of 
transplantable human HSCs.
3.2. ChIP-on-chip and gene expression assays identified important target genes that 
are regulated by SALL4
In their study of SALL4 regulated networks in normal hematopoiesis, Gao et al. have sorted 
human bone marrow and cord blood CD34+ cells, and performed ChIP-on-chip together 
with gene expression assays . This investigation identified that CD34, RUNX1, HOXA9, and 
PTEN are SALL4-directed target genes in these cells. In particular, HOXA9 was characterized 
as a major SALL4 target in normal hematopoiesis . In another study, the polycomb complex 
protein BMI-1 as a critical SALL4 downstream target has been documented [45]. Chromatin 
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 immunoprecipitation coupled with quantitative PCR (ChIP-qPCR) in the 32D myeloid pro-
genitor cells reveals that SALL4 binds to a specific region of Bmi-1 gene promoter, and hetero-
zygous disruption of Sall4 allele significantly reduced BMI-1 expression in bone marrow cells. 
Further, in transgenic mice that constitutively overexpress human SALL4B, there is upregu-
lated expression of BMI-1, whose levels increase in the progression from normal to preleukemic 
(myelodysplastic syndrome [MDS]) and leukemic (acute myeloid leukemia [AML]) stages [45].
3.3. SALL4 roles in normal HSC/HPC capacity maintenance
In human CD34+ cell studies, a shRNA-mediated SALL4 knockdown resulted in decreased in 
vitro myeloid-colony-forming ability and impaired in vivo engraftment. Further, loss of either 
SALL4 or its downstream target HOXA9 expression in CD34+ cells shared a similar pheno-
type. These findings indicate that the role of SALL4 and HOXA9 in normal hematopoiesis is to 
maintain the HSPCs in an undifferentiated stage with self-renewal capacity [37]. Very recently, 
the roles of SALL4 in normal hematopoiesis have been further explored using conditional gene 
targeting approaches in mice [46]. Unexpectedly, wild type Sall4f/f/CreERT2 mice treated with 
tamoxifen or vav-Cre-mediated (hematopoietic-specific) Sall4−/− mice were all healthy and dis-
played no significant hematopoietic defects, which contrasts to previous findings from human 
CD34+ cell studies. Reasons for this discrepancy have not been fully addressed. However, it 
has been speculated that SALL4 may have a redundant role during homeostasis, which can 
be compensated by other Sall gene family members, or pretreatment of gene knockdown may 
not truly reflect the actual performance of gene functions in vitro or in vivo. On the other hand, 
some genes may exert aberrant functions only when cells encounter transplantation or replica-
tive stress (see review [47]), and some vav/Cre knockout models may demonstrate hematopoi-
etic defects at late stages [48]. Therefore, it might be necessary to perform serial transplantation 
and/or stress induction (such as 5-fluorouracil injury) assays with SALL4-deficient cells to fully 
clarify SALL4 effect and mechanisms in normal HSC capacity maintenance.
4. Functions of SALL4 and its regulated networks in leukemia
4.1. SALL4 is aberrantly expressed in human leukemias
SALL4 is absent in most adult tissues and SALL4 expression in bone marrow is restricted 
to the rare CD34+ HSCs/HPCs. However, aberrant expression of SALL4 has been detected 
in various human solid tumors as well as different types of leukemias [49–57]. In patients 
with MDS, a group of preleukemic hematologic disorders, a high level of SALL4 expression 
is detected and correlated with high-risk patients with poor survival [58, 59]. In AML cases, 
our group and others have reported that SALL4 mRNA or proteins are aberrantly expressed 
in various AML subtypes (ranging from M1 to M5, the French-American-British [FAB] clas-
sification), and SALL4 expression is involved in chromosomal instability and associated with 
disease status and drug treatments [59–65]. SALL4 expression is found significantly higher in 
AML patients with complex karyotype (equal to or more than three aberrant karyotypes) than 
that in MDS patients with normal karyotype [63]. In chemotherapy cases, it has been reported 
that SALL4 has the highest expression level in de novo AML patients which then decreases 
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in partial remission (PR), and then even lower in complete remission (CR) [61, 62]. Further, 
SALL4 was found to decrease throughout the treatment process in the drug responsive group 
but increase in drug resistant group [62]. In other leukemia cases, aberrant SALL4 expression 
has been reported in ALK positive anaplastic large cell lymphoma (ALK+ ALCL) [66], B cell 
acute lymphocytic leukemia (B-ALL), most prominently in B-ALL patients with TEL-AML1 
translocation, which is the most common genetic abnormality in pediatric B-ALL [67, 68]. 
SALL4 expression is also detected in precursor B-cell (but not T-cell) lymphoblastic leukemia/
lymphomas [61]. In addition, SALL4 expression has been detected in patient samples from 
blastic stage of chronic myeloid leukemia (CML), as opposed to the chronic phase, and in 
samples from CML patients who have achieved complete remission or those who have tyro-
sine kinase inhibitor resistance [61, 69, 70].
4.2. Role of SALL4 in transgenic model and in MLL-rearranged leukemia
Given the detection of aberrant SALL4 expression in leukemia patients, our research group 
has previously investigated transgenic mice that overexpress either human SALL4A or 
SALL4B. Interestingly, all the SALL4B mice developed MDS-like features at 2 months of age, 
and nine of them (53%) progressed to AML. In contrast, the SALL4A mice did not exhibit 
leukemia formation during the test period [59]. These studies suggest that SALL4B, but 
not SALL4A, has oncogenic activity in inducing leukemogenesis. In mechanism studies, 
the SALL4 isoforms were found to bind β-catenin protein, and these factors synergistically 
enhanced the Wnt/β-catenin signaling pathway. As expected, the expression levels of cyclin-
D1 and c-Myc, the two known targets of the Wnt/β-catenin pathway, were both increased in 
the SALL4B mice bone marrow cells. Interestingly, in a recent study, transgenic activation of 
the SALL4 target β-catenin in osteoblasts, the HSC/HPC niche, also induced MDS and AML 
development. Notably, these β-catenin mutated mice were anemic at as early as 2 weeks and 
died before 6 weeks of age, indicating a severe driving event in leukemogenesis [71]. Further 
in-depth studies are therefore needed to elucidate whether SALL4B in transgenic mice poten-
tially induces leukemogenesis via activating β-catenin in the osteoblastic niche.
Recently, our group explored SALL4 functions in leukemia pathogenesis induced by MLL-AF9, 
one of the most common mixed lineage leukemia (MLL)-rearranged (MLL-r) oncoproteins found 
in leukemia patients which is associated with very poor prognosis [72–76]. A previous study 
showed that SALL4 physically interacts with the MLL wild type protein in regulating HOXA9 
expression [77]. In this study, our data revealed that loss of SALL4 in MLL-AF9-transformed 
bone marrow cells largely disrupted their clonogenic ability in methylcellulose-based medium 
and in liquid culture, induced markable apoptosis and cell cycle arrest at G1. Consistently, 
conditional disruption of both Sall4 alleles in transplanted mice completely blocked leukemia 
initiation and significantly attenuated pre-existing disease progression [46]. Therefore, these 
studies suggest that SALL4 is an essential transcriptional regulator in MLL-r leukemogenesis.
4.3. SALL4 regulated pathways in leukemia
Our research group has previously conducted ChIP-on-chip assays with a promyelocytic leu-
kemic cell line NB4 [78]. Analysis of the SALL4-bound genes revealed the most prominent 
pathways involving WNT/β-catenin, apoptosis, NOTCH signaling, the polycomb complex 
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Figure 3. Key signaling pathways bound by SALL4 in NB4 acute promyelocytic and MLL-AF9 transformed leukemic 
cells.
protein BMI-1, PTEN, and nuclear factor-kB (see Figure 3). When the cells were treated with a 
SALL4-specific shRNA vector, the expression levels of proapoptotic genes TNF, TP53, PTEN, 
CARD9, CARD11, ATF3, and LTA were upregulated. In contrast, the expression levels of anti-
apoptotic genes such as BCL2, BMI-1, DAD1, TEGT, BIRC7, and BIRC4 (XIAP) are downregu-
lated. In line with the expression studies, reduction of SALL4 also diminished tumorigenicity 
of leukemic cells in immunodeficient mice. Further, the SALL4 knockdown-induced apopto-
sis was reversed by ectopic expression BMI-1. In a separate study, SALL4 knockdown in com-
bination with a BCL-2 inhibitor also synergistically increased apoptosis in AML cells. Other 
studies have reported that SALL4 recruits the nucleosome remodeling and histone deacety-
lation (NuRD/HDAC) repressive complex to the promoter of PTEN and decrease its gene 
expression [79], while conversely, a SALL4-derived peptide blocking this protein-protein 
interaction resulted in notable leukemic cell death, and this effect was reversed by treatment 
of a PTEN inhibitor [80]. In AML differentiation studies, SALL4 expression has also been 
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reported to block all-trans retinoic acid (ATRA)-induced myeloid differentiation in ATRA-
sensitive and -resistant AML cells. Further, inhibition of SALL4 and its interacting epigenetic 
factor LSD1 synergistically promoted ATRA-induced cell differentiation and growth arrest. 
In mechanistic studies, SALL4 and LSD1 have been found to co-occupy on the ATRA targets 
RARβ, ID2, and CYP26 gene promoters, and cooperatively regulate their expression [81–82].
Recently, our research group also conducted ChIP assays with sequencing (ChIP-Seq) assays 
with MLL-AF9 transformed murine leukemic cells. This study revealed that SALL4 binds to 
the key MLL-AF9 target genes Meis1, Hoxa9; MLL-r leukemia related genes Cebpα, Id2, Elf1, Evl, 
Flt3, Nf1, Tal1, Tcf7l1, Nkx2–3; the Hox factors Hoxa-9, −10, −11, −13; the Notch ligand Jag2, and 
Wnt/β-catenin regulator Wnt7b (see Figure 3 and [46]). mRNA microarrays assays following 
early Sall4 deletion identified multiple upregulated genes including cell cycle inhibitors Cdkn1a 
(p21), Trp53inp1; HSC/HPC colony-forming repressor Slfn2; and hematopoietic differentiation 
markers Col5a1, Fyb, Irf8 and Pira6. In contrast, the TGFβ family genes, Tgfβ2, Tgfβ3, Tgfβr3, and 
the genes related to chemo-resistance or leukemia aggressiveness, such as Thbs1, Tgm2, and 
Ambp were downregulated [46, 83]. In comparison with the mRNA expression data, not many 
of the ChIP-Seq-identified SALL4 targets were associated with early expression changes. This 
limited overlap has been considered to be related to the length of time of SALL4 inactivation, 
the presence of other co-regulators in play, and/or the relatively lower number of genes identi-
fied in relevant assays. More detailed studies would help to address these issues.
4.4. SALL4 regulates different downstream networks in normal and leukemic cells
In the SALL4-binding genes identified in NB4 leukemia and those in normal CD34+ cells, 
less than 20% of the targets were found commonly bound by SALL4. This limited overlap 
mirrors the findings from ESC and XEN cell promoter binding studies, and further indi-
cates that SALL4 functions in a manner specific to cell type or cell context (see Figure 4). 
Particularly, downregulation of SALL4 expression seems to have an opposite effect on 
genes involved apoptosis. For example, in leukemic cells, when SALL4 was downregu-
lated along with the apoptotic phenotype, the expression levels of proapoptosis genes TRO 
Figure 4. SALL4 functions in a manner specific to cell type or cell context. Shown are main effects following SALL4 
knockdown in indicated cell types.
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Figure 5. The SALL4-associated epigenetic factors. DNMTs: DNA methyltransferases. HDACs: histone deacetylases. 
HDMs: histone demethylases. HMTs: histone methyltransferases.
and ABL1 increased, and the expression of anti-apoptosis gene BCL2 decreased. While in 
CD34+ cells, there was no notable apoptosis with SALL4 knockdown, and the expression 
of BCL2 increased whereas the expression of TRO and ABL1 decreased. This differential 
regulatory effect by SALL4 should be helpful in developing SALL4-targeted anti-leukemia 
strategies to spare normal blood cells.
5. Epigenetic mechanisms involved in SALL4’s regulatory functions
5.1. SALL4 interacts with a variety of epigenetic factors to regulate downstream 
gene expression
So far the reported SALL4-interacting epigenetic factors (see Figure 5) include: DNA methyl-
transferases DNMT-1, -3A, -3B, -3 L, methyl-CpG-binding domain 2 protein (MBD2) [84]; NuRD 
complex that contains histone deacetylases HDAC1/2 [79]; H3K4 methyltransferase MLL1 [77]; 
H3K79 methyltransferase DOT1L [46]; H3K36 methyltransferase Wolf-Hirschhorn syndrome 
candidate 1 (WHSC1) [85, 86]; and lysine-specific histone demethylase LSD1/KDM1A [46, 81, 
87]. All of these are critical regulators in normal blood development and are frequent targets for 
dysregulation in hematological malignancies [88–90], and clinical epigenetic remedies inhibit-
ing such epigenetic factors have been shown effective in treating leukemia [91–93]. In fact, in 
MLL-AF9-mediated mouse AML studies, genetic disruption of either SALL4, DNMT1, LSD1, 
or DOT1L likewise blocked leukemia initiation and delayed disease progression in vivo [94–96].
By interacting with specific epigenetic factors, SALL4 expression can affect DNA methylation 
and histone methylation/acetylation status at genes that control hematopoietic differentiation, 
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apoptosis, tumor induction or suppression. For example, in NB4 AML cells that were transduced 
with a lentiviral SALL4 vector, there was an overall increased percentage of DNA methylation 
at various CpG sites of tumor suppression gene PTEN, which co-relates with a downregulated 
gene transcription [84]. In mouse bone marrow LSK cells, overexpression of SALL4 also induced 
increased percentage of methylation at the CpG sites of early B-cell factor 1 (Ebf1) promoter, as 
well as the Sall4 gene promoter itself, which facilitates an undifferentiated cellular status [84]. 
Similarly, the SALL4 overexpression levels significantly affected LSD1 binding and altered 
H3K4me2 levels at the promoter regions of tumor necrosis factor (Tnf) and differentiation-related 
genes EBF1, GATA1, RARβ, ID2, and CYP26, which are associated with relevantly altered gene 
transcription levels [81, 87]. Also, while SALL4 interacts with the NuRD/HDAC1/2 complex to 
silence PTEN promoter via reduced acetylation of histone H3 at its binding sites, the SALL4-
derived peptide blocks this interaction and leads to reactivated PTEN expression. Additionally, 
in the 32D myeloid progenitor cells following lentiviral SALL4 transduction, the H3K4me3 and 
H3K79me2/3 levels at Bmi1 promoter regions were increased [45]. In MLL-AF9 leukemia studies, 
the expression levels of SALL4 also affected LSD1 and Dot1l binding and relevant H3K4me3 and 
H3K79me3 amounts at the promoter regions of Meis1 and multiple HOX family genes in bone 
marrow cells [46, 77, 79].
5.2. SALL4 regulated epigenetic modification programs are cell type-dependent
Consistent with the findings from SALL4 genome-wide promoter binding and relevant expres-
sion assays, SALL4-regulated epigenetic modification programs are also strictly dependent 
on the cellular context. As reported, SALL4-bound genomic loci in murine ESCs are largely 
enriched for the activating marker H3K4me3, which indicates an association of SALL4 with 
non-repressed genes. In XEN cells, however, SALL4-binding loci displayed significantly less 
H3K4me3 enrichment. Instead, most of these regions are either accompanied with H3K27me3 
or lacking both H3K4me3 and H3K27me3, the “epi-markers” frequently associated with gene 
repression [26]. In our MLL-AF9 leukemia model studies, SALL4 has been shown to recruit 
DOT1L and LSD1 to Meis1 and HOX family gene promoters and modulate their H3K79me2/3 
and H3K4me3 levels [46]. The previously demonstrated SALL4-MLL interaction may con-
tribute to the observed HEK4me3 changes. However, in some non-MLL-r human AMLs, 
the DOT1L-regulated H3K79 methylation may not play a role, and it has been reported that 
administration of DOT1l inhibitors sensitized chemotherapy in MLL-r but not in non-MLL-r 
AML cells [97]. Further, the DOT1L recruitment to MLL-AF9 has been associated with the 
level of leukemic transformation [98–100]. Therefore, one may anticipate that SALL4 differ-
entially interacts with individual epigenetic factors to exerting a disease/subtype–dependent 
regulatory effect. This concept, if proven true, should further facilitate the development of 
SALL4-based disease subtype–specific anti-leukemia strategies.
6. Conclusions
Abnormal expression of SALL4 has been frequently detected in different types of human 
leukemias and associated with disease status and drug treatments. On the other hand, 
proper manipulation of SALL4 expression might be useful in achieving clinically significant 
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 expansion of transplantable human HSCs. Therefore, understanding how SALL4 mecha-
nisms maintain normal HSCs/HPCs vs. leukemic cells will facilitate development of newer, 
more efficient therapies in clinic.
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ESC embryonic stem cell
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B-ALL B cell acute lymphocytic leukemia
CML chronic myeloid leukemia
MLL-r mixed lineage leukemia (MLL)-rearranged
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NuRD/HDAC nucleosome remodeling and histone deacetylation
ATRA all-trans retinoic acid
ChIP-Seq ChIP assays with sequencing
MBD2 methyl-CpG-binding domain 2 protein
WHSC1 Wolf-Hirschhorn syndrome candidate 1
Ebf1 early B-cell factor 1
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